Kite Pharma prices IPO at $17, above the range

By
A A A

Kite Pharma, a biotech developing cancer immunotherapies with the National Cancer Institute, raised $128 million by offering 7.5 million shares at $17, above the upwardly revised range of $15 to $16. Kite Pharma plans to list on the NASDAQ under the symbol KITE. Kite Pharma initially filed confidentially on 4/4/2014. Jefferies & Co., Credit Suisse and Cowen & Company acted as lead managers on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: KITE

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

64,789,752
  • $117.60 ▼ 0.86%
53,107,118
  • $10.39 ▼ 1.05%
42,600,857
  • $17.10 ▼ 0.47%
36,917,582
  • $11.02 ▼ 0.36%
34,902,121
  • $40.75 ▼ 0.10%
31,489,742
  • $15.68 ▲ 0.06%
31,037,743
  • $75.63 ▲ 2.19%
29,605,187
  • $10.11 ▼ 0.69%
As of 11/25/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com